Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03570892
Title Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

B-cell lymphoma

Therapies

Lenalidomide

Ibrutinib

Carboplatin + Etoposide + Ifosfamide + Rituximab

Carmustine + Cytarabine + Etoposide + Melphalan

Cisplatin + Dexamethasone + Gemcitabine + Rituximab

Cyclophosphamide + Fludarabine + Tisagenlecleucel

Cisplatin + Cytarabine + Dexamethasone + Rituximab

Gemcitabine + Oxaliplatin + Rituximab

Bendamustine + Fludarabine + Tisagenlecleucel

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | BEL | AUT

Facility Status City State Zip Country Details
Moores UC San Diego Cancer Center La Jolla California 92093 United States Details
University of California Los Angeles University of California LA Los Angeles California 90095 United States Details
UCSF Medical Center San Francisco California 94143 United States Details
Sarah Cannon Research Institute Denver Colorado 80218 United States Details
Mayo Clinic Jacksonville Jacksonville Florida 32224 United States Details
Emory University School of Medicine/Winship Cancer Institute SC Atlanta Georgia 30322 United States Details
University of Chicago Medical Center Hematology and Oncology Chicago Illinois 60637 United States Details
University of Kansas Cancer Center SC Kansas City Kansas 66205 United States Details
Wayne State University - Karmanos Cancer Institute SC Detroit Michigan 48201 United States Details
University of Nebraska Medical Center Omaha Nebraska 68198 United States Details
Hackensack University Medical Center Hackensack New Jersey 07601 United States Details
Jewish Hospital Cincinnati Ohio 45236 United States Details
The Ohio State University SC Columbus Ohio 43210 United States Details
Oregon Health Sciences Univ SC Portland Oregon 97239 United States Details
University of Pennsylvania, Abramson Cancer Center Philadelphia Pennsylvania 19104 United States Details
MUSC Hollings Cancer Center Charleston South Carolina 29425 United States Details
Sarah Cannon Research Institute Nashville Tennessee 37203 United States Details
St Davids South Austin Medical Ctr Austin Texas 78704 United States Details
Baylor Scott and White Research Institute Dallas Texas 75231 United States Details
University of Texas MD Anderson Cancer Center MD Anderson Cancer Center Houston Texas 77030 United States Details
Methodist Hospital San Antonio Texas 78229 United States Details
University of Wisconsin Carbone Cancer Center Madison Wisconsin 53792-6164 United States Details
Novartis Investigative Site Darlinghurst New South Wales 2010 Australia Details
Novartis Investigative Site Melbourne Victoria 3000 Australia Details
Novartis Investigative Site Murdoch Western Australia 6150 Australia Details
Novartis Investigative Site Salzburg 5020 Austria Details
Novartis Investigative Site Vienna A-1090 Austria Details
Novartis Investigative Site Leuven 3000 Belgium Details
Novartis Investigative Site Salvador BA 41253-190 Brazil Details
Novartis Investigative Site Sao Paulo 05651-901 Brazil Details
Novartis Investigative Site Beijing 100036 China Details
Novartis Investigative Site Beijing 100191 China Details
Novartis Investigative Site Shanghai China Details
Novartis Investigative Site Lille Cedex 59037 France Details
Novartis Investigative Site Montpellier cedex 5 34295 France Details
Novartis Investigative Site Nantes Cedex 1 44093 France Details
Novartis Investigative Site Paris Cedex 10 75475 France Details
Novartis Investigative Site Pierre Benite Cedex 69495 France Details
Novartis Investigative Site Toulouse 31059 France Details
Novartis Investigative Site Regensburg Bavaria 93053 Germany Details
Novartis Investigative Site Berlin 13353 Germany Details
Novartis Investigative Site Hamburg 20246 Germany Details
Novartis Investigative Site Koeln 50937 Germany Details
Novartis Investigative Site Leipzig 04103 Germany Details
Novartis Investigative Site Muenchen 81377 Germany Details
Novartis Investigative Site Ulm 89081 Germany Details
Novartis Investigative Site Hong Kong Hong Kong Details
Novartis Investigative Site Milano MI 20133 Italy Details
Novartis Investigative Site Rozzano MI 20089 Italy Details
Novartis Investigative Site Roma RM 00168 Italy Details
Kyushu University Hospital Fukuoka city Fukuoka 812-8582 Japan Details
Hokkaido University Hospital Sapporo city Hokkaido 060 8648 Japan Details
Tohoku University Hospital Sendai city Miyagi 980 8574 Japan Details
Amsterdam UMC, locatie AMC Amsterdam 1105 AZ Netherlands Details
UMC Utrecht Cancer Center Utrecht 3584CX Netherlands Details
Novartis Investigative Site Oslo NO 0424 Norway Details
Novartis Investigative Site Singapore 119228 Singapore Details
Novartis Investigative Site Singapore 169608 Singapore Details
Novartis Investigative Site Salamanca Castilla Y Leon 37007 Spain Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Hospitalet de LLobregat Catalunya 08907 Spain Details
Novartis Investigative Site Madrid 28009 Spain Details
Novartis Investigative Site Madrid 28041 Spain Details
Novartis Investigative Site Zurich 8091 Switzerland Details
Novartis Investigative Site Taipei 10002 Taiwan Details
Novartis Investigative Site Birmingham B15 2TH United Kingdom Details
Novartis Investigative Site London WC1E 6HX United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field